|Articles|September 14, 2021
- Pharmaceutical Executive-09-01-2021
- Volume 41
- Issue 9
Pharmaceutical Executive, September 2021 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive September 2021 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 5 years ago
When Innovation Outpaces HTA, Access Struggles to Keep Upalmost 5 years ago
Doubling Down On Innovation, Recoveryalmost 5 years ago
Developing a Product Launch Strategy for an Orphan Drugalmost 5 years ago
Investing for Success: Finding the Right Launch Balancealmost 5 years ago
Rethinking Obesity: Wegovyalmost 5 years ago
Fear Factor: Palforziaalmost 5 years ago
Formidable Option: Orgovyxalmost 5 years ago
No Small Feat: Nurtec ODTalmost 5 years ago
‘Rare’ Reinforcement: Evrysdialmost 5 years ago
Serial Problem SolverAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Otsuka’s First-In-Class Simtriyo for Adults & Pediatric Patients
2
argenx Acquires Forte Biosciences for $2.2 Billion
3
Where the True Bottlenecks Exist at FDA for Clinical Trials
4
Moving From Symptom Management to Disease Modification in Parkinson’s Research: Q&A with Dr. Jan Stoehr
5